Cytomx Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytomx Therapeutics, Inc. (CTMX) on September 21, 2022. The report addresses a change in the Company's senior financial leadership effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Carlos Campoy, Senior Vice President, Chief Financial Officer, and former principal financial and accounting officer, is departing the Company. His employment is expected to terminate effective September 30, 2022.
- Appointment of Interim CFO: Chris Ogden, Senior Vice President, Finance and Accounting, has been designated to assume the responsibilities of principal financial officer and principal accounting officer effective immediately.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies related to the leadership transition are disclosed beyond the standard reporting of the event. There are no reported family relationships or related party transactions involving Mr. Ogden.
Key Facts for Investor Verification
- Confirm the exact termination date of Carlos Campoy (expected September 30, 2022).
- Verify the duration of Chris Ogden's interim role and whether a permanent CFO search is underway.
- Review the Company's most recent 10-Q or 10-K for the latest financial position, as this 8-K contains no financial data.